ViaCyte, Inc., a pioneering biotechnology company headquartered in the United States, focuses on innovative cell therapy solutions for diabetes management. Founded in 2004, ViaCyte has made significant strides in the development of its unique product offerings, including its lead product, PEC-Direct, which aims to restore insulin production in patients with type 1 diabetes. With a strong presence in the regenerative medicine sector, ViaCyte is dedicated to advancing its proprietary technologies that utilise stem cell-derived pancreatic islet cells. The company has garnered attention for its commitment to addressing the challenges of diabetes, positioning itself as a leader in the field. Through its groundbreaking research and development efforts, ViaCyte continues to make notable contributions to the future of diabetes treatment.
We don't have data for ViaCyte, Inc., but we can show you information about their parent organization instead.
View parent company